A test of the predictive validity of animal models of schizophrenia based on phencyclidine and d-amphetamine

Neuropsychopharmacology

Volumn 18, Issue 4, 1998, Pages 293-304

  Sams Dodd, Frank ^a  

^a H Lundbeck   (Denmark)

Author keywords

Amphetamine; Antipsychotics; Negative symptoms; Phencyclidine; Positive symptoms; Rat; Schizophrenia

Indexed keywords

DEXAMPHETAMINE; HALOPERIDOL; NEUROLEPTIC AGENT; PHENCYCLIDINE;

ANIMAL MODEL; ARTICLE; CENTRAL NERVOUS SYSTEM; CONTROLLED STUDY; DRUG COMPETITION; HUMAN; MALE; PRIORITY JOURNAL; SCHIZOPHRENIA; SOCIAL INTERACTION;

ANIMALS; ANTIPSYCHOTIC AGENTS; BEHAVIOR, ANIMAL; CLOZAPINE; DEXTROAMPHETAMINE; DISEASE MODELS, ANIMAL; DOPAMINE UPTAKE INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; HALLUCINOGENS; HALOPERIDOL; MALE; MOTOR ACTIVITY; PHENCYCLIDINE; PREDICTIVE VALUE OF TESTS; RATS; RATS, WISTAR; SCHIZOPHRENIA; SOCIAL BEHAVIOR; STEREOTYPED BEHAVIOR;

EID: 0031909405     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0893-133X(97)00161-9     Document Type: Article

References (34)

1. Angist B, Lee HK, Gershon S The antagonism of amphetamine-induced symptomatology by a neuroleptic. Am J Psychiatry. 131:1974;817-819.
2. Arnt J Differential effects of classical and newer antipsychotics on the hypermotility induced by two levels of D-amphetamine. Eur J Pharmacol. 283:1995;55-62.
3. Baldessarini RJ, Centorrino F, Flood JG, Volpicelli SA, Huston-Lyon D, Cohen BM Tissue concentrations of clozapine and its metabolites in the rat. Psychopharmacology. 9:1993;117-124.
4. Borison RL, Diamond BI, Sinha D, Gupta RP, Ajiboye PA Clozapine withdrawal rebound psychosis. Psychopharmacol Bull. 24:1988;260-263.
5. Breier A, Buchanan RW, Kirkpatrick B, Davis OR, Irish D, Summerfelt A, Carpenter WT Effects of clozapine on positive and negative symptoms in outpatients with schizophrenia. Am J Psychiatry. 151:1994;20-26.
6. Bunny BS, Grace AA Acute and chronic haloperidol treatment. Comparison of effects on nigral dopaminergic cell activity Life Sci. 23:1978;1715-1728.
7. Burt D, Creese I, Snyder S Antischizophrenic drugs. Chronic treatment elevated dopamine receptor binding in brain Science. 196:1977;326-328.
8. Castellani S, Adams PM Acute and chronic phencyclidine effects on locomotor activity, stereotypy and ataxia in rats. Eur J Pharmacol. 73:1981;143-154.
9. Castellani S, Giannini AJ, Boeringa JA, Adams PM Phencyclidine intoxication. Assessment of possible antidotes J Toxicol Clin Toxicol. 19:1982;313-319.
10. Cheng YF, Paalzow LK Linear pharmacokinetics of haloperidol in the rat. Biopharm Drug Dispos. 13:1992;69-76.
11. Connell PH Amphetamine Psychosis. 1958;Chapman & Hall, London.
12. Ellenbroek BA, Cools AR Animal models with construct validity for schizophrenia. Behav Pharmacol. 1:1990;469-490.
13. File SE The use of social interaction as a method for detecting anxiolytic activity of chlordiazepoxide-like drugs. J Neurosci Methods. 2:1980;219-238.
14. Freed WJ The therapeutic latency of neuroleptic drugs and nonspecific postjunctional supersensitivity. Schizophr Bull. 14:1988;269-277.
15. Geyer M, Swerdlow NR, Mansbach RS, Braff DL Startle response models of sensorimotor gating and habituation deficits in schizophrenia. Brain Res Bull. 25:1990;485-498.
16. Giannini AJ, Loiselle RH, Price WA, Giannini MC Chlorpromazine vs. meperidine in the treatment of phencyclidine psychosis. J Clin Psychiatry. 46:1985;52-54.
17. Huitema BE The Analysis of Covariants and Alternatives. 1980;Wiley & Sons, New York.
18. Jackson DM, Johansson C, Lindgren LM, Bengtson A Dopamine receptor antagonists block amphetamine and phencyclidine-induced motor stimulation in rats. Pharmacol Biochem Behav. 41:1994;465-471.
19. Jann MW, Grimsley SR, Gray EC, Chang WH Pharmacokinetics and pharmacodynamics of clozapine. Clin Pharmacokinet. 24:1993;161-176.
20. Khot V, DeVane CL, Korpi ER, Venable D, Bigelow LB, Wyatt RJ, Kirch DG The assessment and clinical implications of haloperidol acute-dose, steady-state, and withdrawal pharmacokinetics. J Clin Psychopharmacol. 13:1993;120-127.
21. Leikin JB, Krantz AJ, Zell-Kanter M, Barkin RL, Hryhorczuk DO Clinical features and management of intoxication due to hallucinogenic drugs. Med Toxicol Adverse Drug Exp. 4:1989;324-350.
22. Lin SK, Chang WH, Chung MC, Lam YW, Jann MW Disposition of clozapine and desmethylclozapine in schizophrenic patients. J Clin Pharmacol. 34:1994;318-324.
23. Murray TF, Horita A Phencyclidine-induced stereotyped behavior in rats. Dose response effects and antagonism by neuroleptics Life Sci. 24:1979;2217-2226.
24. Nyberg S, Nordström A-L, Halldin C, Farde L Position emission tomography studies on D2 dopamine receptor occupancy and plasma antipsychotic drug levels in man. Int Clin Psychopharmacol. 10:1995;81-85.
25. Robinson TE, Becker JB Enduring changes in brain and behavior produced by chronic amphetamine administration. A review and evaluation of animal models of amphetamine psychosis Brain Res Rev. 11:1986;157-198.
26. Sams-Dodd F Distinct effects of d-amphetamine and phencyclidine on the social behaviour of rats. Behav Pharmacol. 6:1995;55-65.
27. Sams-Dodd F Automation of the social interaction test by a video tracking system. Behavioural effects of repeated phencyclidine treatment J Neurosci Methods. 59:1995;157-168.
28. Sams-Dodd F Phencyclidine-induced stereotyped behaviour and social isolation in the rat. A possible animal model of schizophrenia Behav Pharmacol. 7:1996;3-23.
29. Sams-Dodd F Effect of novel antipsychotic drugs on PCP-induced stereotyped behaviour and social isolation in the rat social interaction test. Behav Pharmacol. 8:1997;196-215.
30. Siegel RK Phencyclidine and ketamine intoxication a study of 4 populations of recreational users. Peterson RC, Stillman RC National Institute of Drug Abuse Research Monograph #21. 1978;119-147 NIH Press, Washington, DC.
31. Skarsfeldt T Electrophysiological profile of the new atypical neuroleptic, sertindole, on midbrain dopamine neurones in rats. Acute and repeated treatment Synapse. 10:1992;25-33.
32. Vahid-Ansari F, Nakabeppu Y, Robertson GS Contrasting effects of chronic clozapine, seroquel, and haloperidol administration on FosB-like immunoreactivity in the rodent forebrain. Eur J Neurosci. 8:1996;927-936.
33. Viguera AC, Baldessarini RJ, Hegarty JD, van Kammen DP, Tohen M Clinical risk following abrupt and gradual withdrawal of maintenance neuroleptic treatment. Arch Gen Psychiatry. 54:1997;49-55.
34. Willner P The validity of animal models of depression. Psychopharmacology. 83:1984;1-16.